| Mrs Crystal Lee Komp, CNM | |
|
N8150 Amundson Coulee Rd, Holmen, WI 54636 | |
| (717) 343-8744 | |
| Not Available |
| Full Name | Mrs Crystal Lee Komp |
|---|---|
| Gender | Female |
| Speciality | Advanced Practice Midwife |
| Location | N8150 Amundson Coulee Rd, Holmen, Wisconsin |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1770252173 | NPI | - | NPPES |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Crystal Lee Komp, CNM N8150 Amundson Coulee Rd, Holmen, WI 54636 Ph: (717) 343-8744 | Mrs Crystal Lee Komp, CNM N8150 Amundson Coulee Rd, Holmen, WI 54636 Ph: (717) 343-8744 |
News Archive
Three low-carb meals within 24 hours lowers post-meal insulin resistance by more than 30 percent, but high-carb meals sustain insulin resistance, a condition that leads to high blood pressure, prediabetes and diabetes, according to a University of Michigan study.
Researchers at Mount Sinai School of Medicine have found a potential new treatment for osteonecrosis, or the death of bone tissue, in people who are treated with steroids for several common medical conditions. There are currently no treatment options for people with this debilitating disease. The research is published in the April 27 issue of Proceedings of the National Academy of Sciences.
Allergan, Inc. announced today that the United States District Court for the District of Delaware ruled in favor of Allergan, Inc. in its patent infringement suit against Exela PharmSci, Inc., Exela PharmSci Pvt., Ltd. ("Exela"), Apotex, Inc. and Apotex Corp. ("Apotex") (collectively, the "Defendants") for seeking to market purported generic versions of Allergan's drugs ALPHAGAN® P (brimonidine tartrate ophthalmic solution) 0.1% and 0.15%. Specifically, after a trial in March of 2009, the Court ruled today that all five patents (U.S. Patent Nos. 6,627,210; 6,641,834; 6,673,337; 6,562,873; and 5,424,078) asserted by Allergan are valid and enforceable, that Apotex's proposed generic versions of ALPHAGAN® P 0.1% and 0.15% infringe each of the five patents, and that Exela's proposed generic version of ALPHAGAN® P 0.15% infringes U.S. Patent No. 6,641,834, which was the only patent asserted against it. Pursuant to the Hatch-Waxman Act, the United States Food and Drug Administration is required to delay approval of Defendants' proposed generic products until the last to expire of the infringed patents, which is 2022.
Merck & Co., Inc. today announced financial results for the third quarter of 2009. The company reported non-GAAP (generally accepted accounting principles) earnings per share (EPS) for the quarter of $0.90, which excludes a $1.7 billion after-tax gain from the sale of the company's interest in Merial Limited as well as restructuring charges and pre-closing merger-related expenses. Third-quarter GAAP EPS was $1.61.
Outside of Asia, Denmark became the first nation to ease the forced social distancing norms or lockdown. Last week on Thursday, the officials declared that since the removal of the lockdown, there had been no rise in the number of COVID-19 cases. Their easing of the lockdown rules has been gradual, say the officials, and this process began in mid-April. There have been 9,721 reported cases and 484 deaths due to COVID-19 to date. The number of cases has also declined since 7th April.
› Verified 9 days ago